Aliceblue ANTInstall and trade smarter everywhere
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Concord Biotech Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
Key metrics and details at a glance.
Price Band
₹741
Per ShareLot Size
20 Shares
Minimum Investment
₹14,820
Issue Size
₹1,475.26 Cr
Face Value
₹1
Per ShareIPO Type
Book Building
Retail Quota
35%
QIB Quota
50%
NII Quota
15%
Important dates for your applying strategy.
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
29.4%
Issue Type
Book Building
ISIN
INE338H01029
Concord Biotech Limited is an India-based biopharma company and one of the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology in terms of market share, based on volume in 2022. The Company had (i) 23 APIs across immunosuppressants, oncology and anti-infectives, and (ii) 77 approved products for formulations. The Company has over 200 customers in over 70 countries as of March 31, 2023 for its APIs and formulations.
The oncology drug market is the largest segment among the therapeutic areas in the API market, with a sales value of USD 42 billion (Rs.3,466 billion) in 2022. The anti-infectives market is one of the largest segments by sales value among the therapeutic areas in the API market, with a sales value of USD 32 billion (Rs. 2,643 billion) in 2022. Immunosuppressants market was valued at USD 16 billion (Rs. 1,298 billion) and the global small molecule fermentation API market was valued at USD 11 billion (Rs. 925 billion) in 2022.
Revenue, profit after tax and total assets across the last 3 reported financial years.
Amount in ₹ crore
How the company plans to utilize IPO proceeds.
The funds raised through this IPO will be used for:
Initial public offer of 20,925,652* equity shares of face value of Re. 1 each ("Equity Shares") of Concord Biotech Limited ("Company") for cash at a price of Rs. 741 per equity share (including a premium of Rs. 740 per equity share) ("Offer Price") aggregating to Rs. 1550.52*^ crores (the "Offer") through an offer for sale of 20,925,652* equity shares aggregating to Rs. 1550.52*^ crores by Helix Investment Holdings Pte. Limited (the "Selling Shareholder") and such equity shares offered by the selling shareholder, the ("Offered Shares"). The offer includes a reservation of 10,000* equity shares, aggregating to Rs. 0.67^ crores (constituting 0.01% of the post-offer paid-up equity share capital), for subscription by eligible employees ("Employee Reservation Portion"). The offer less the employee reservation portion is hereinafter referred to as "Net Offer". The offer and net offer constitute 20% and 19.99%, of the post-offer paid-up equity share capital of the company, respectively. The face value of equity shares is Re. 1 each. The offer price is Rs. 741 times the face value. *Subject to finalisation of basis of allotment. ^A discount of Rs. 70 per equity share was offered to eligible employees bidding in the employee reservation portion.
*Subject to approvals and market conditions.
Key competitive advantages and factors to consider before investing.
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
Concord Biotech Limited was originally incorporated as `Servomed Pharmaceuticals Private Limited' at Ahmedabad, Gujarat as a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated November 23, 1984, issued by the Registrar of Companies, Gujarat, at Ahmedabad ("RoC"). Thereafter, an application dated June 24, 1985 was filed for undertaking the change in the name of the company to "Concord Pharmaceuticals Private Limited', pursuant to which a revised certificate of incorporation dated September 24, 1985 was issued by the RoC. Subsequently, with effect from December 26, 1986, Concord Pharmaceuticals Private Limited deemed to have become a public company pursuant to Section 43A of Companies Act, 1956. Thereafter, the name of the Company was changed to 'Concord Biotech Limited' and a fresh certificate of incorporation dated February 16, 2001 was issued by the RoC. Subsequently, the Company became a public company from a deemed public company and a fresh certificate of incorporation dated November 7, 2001 was issued by the RoC.
Wholesalers and Retailers
Amount in ₹ crore
Amount in ₹ crore
Figures in ₹ crore, on a consolidated basis, as reported for FY24 to FY26.